OBJECTIVE: To quantify effect on mortality of administering human albumin or plasma protein fraction during management of critically ill patients. DESIGN: Systematic review of randomised controlled trials comparing administration of albumin or plasma protein fraction with no administration or with administration of crystalloid solution in critically ill patients with hypovolaemia, burns, or hypoalbuminaemia. SUBJECTS: 30 randomised controlled trials including 1419 randomised patients. MAIN OUTCOME MEASURE: Mortality from all causes at end of follow up for each trial. RESULTS: For each patient category the risk of death in the albumin treated group was higher than in the comparison group. For hypovolaemia the relative risk of death after albumin administration was 1.46 (95% confidence interval 0.97 to 2.22), for burns the relative risk was 2.40 (1.11 to 5.19), and for hypoalbuminaemia it was 1.69 (1.07 to 2.67). Pooled relative risk of death with albumin administration was 1.68 (1.26 to 2.23). Pooled difference in the risk of death with albumin was 6% (95% confidence interval 3% to 9%) with a fixed effects model. These data suggest that for every 17 critically ill patients treated with albumin there is one additional death. CONCLUSIONS: There is no evidence that albumin administration reduces mortality in critically ill patients with hypovolaemia, burns, or hypoalbuminaemia and a strong suggestion that it may increase mortality. These data suggest that use of human albumin in critically ill patients should be urgently reviewed and that it should not be used outside the context of rigorously conducted, randomised controlled trials.
OBJECTIVE: To quantify effect on mortality of administering human albumin or plasma protein fraction during management of critically illpatients. DESIGN: Systematic review of randomised controlled trials comparing administration of albumin or plasma protein fraction with no administration or with administration of crystalloid solution in critically illpatients with hypovolaemia, burns, or hypoalbuminaemia. SUBJECTS: 30 randomised controlled trials including 1419 randomised patients. MAIN OUTCOME MEASURE: Mortality from all causes at end of follow up for each trial. RESULTS: For each patient category the risk of death in the albumin treated group was higher than in the comparison group. For hypovolaemia the relative risk of death after albumin administration was 1.46 (95% confidence interval 0.97 to 2.22), for burns the relative risk was 2.40 (1.11 to 5.19), and for hypoalbuminaemia it was 1.69 (1.07 to 2.67). Pooled relative risk of death with albumin administration was 1.68 (1.26 to 2.23). Pooled difference in the risk of death with albumin was 6% (95% confidence interval 3% to 9%) with a fixed effects model. These data suggest that for every 17 critically illpatients treated with albumin there is one additional death. CONCLUSIONS: There is no evidence that albumin administration reduces mortality in critically illpatients with hypovolaemia, burns, or hypoalbuminaemia and a strong suggestion that it may increase mortality. These data suggest that use of human albumin in critically illpatients should be urgently reviewed and that it should not be used outside the context of rigorously conducted, randomised controlled trials.
Authors: C Jelenko; J B Williams; M L Wheeler; B D Callaway; V K Fackler; C A Albers; A A Barger Journal: Crit Care Med Date: 1979-04 Impact factor: 7.598